Vértiz-Hernández ÁA, Martínez-Morales F, Valle-Aguilera R, López-Sánchez P, Villalobos-Molina R, Pérez-Urizar J

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 250-257
Archivo PDF: 204.28 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Adams RJ, Appleton SL, Gill TK, Taylor AW, Wilson DH, Hill CL. Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study. BMC Fam Pract. 2011;12:70.

2. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010;16:5651-61.

3. Wang Q, Takei Y, Kobayashi O, Osada T, Watanabe S. Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J Clin Biochemi Nutr. 2009;45:163-70.

4. Geusens P, Lems W. Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. Ther Clin Risk Manag. 2008;4:337-44.

5. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other NSAIDs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med. 2009;169:115-21.

6. Chiu Y-J, Huang T-H, Chiu C-S, et al. Analgesic and Antiinflammatory Activities of the Aqueous Extract from Plectranthus amboinicus (Lour.) Spreng. Both In Vitro and In Vivo. Evid Based Complement Alternat Med. 2012;2012:508137.

7. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol. 2009;76:1053-61.

8. Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007;152:1185-95.

9. Seta F, Rahmani M, Turner PV, Funk CD. Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One. 2011;6:e23439.

10. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol. 2008;59:117-33.

11. McKellar G, Singh G. Celecoxib in arthritis: relative risk management profile and implications for patients. Ther Clin Risk Manag. 2009;5:889-96.

12. Hegazy R, Alashhab M, Amin M. Cardiorenal effects of newer NSAIDs (celecoxib) versus classic NSAIDs (ibuprofen) in patients with arthritis. J Toxicol. 2011;2011:862153.

13. Elseify ZA, El-Khattab SO, Khattab AM, Atta EM, Ajjoub LF. Combined parecoxib and I.V. paracetamol provides additional analgesic effect with better postoperative satisfaction in patients undergoing anterior cruciate ligament reconstruction. Saudi J Anaesth. 2011;5:45-9.

14. Wei W, Zhao T and Li Y. Efficacy and safety of parecoxib sodium for acute postoperative pain: A meta-analysis. Exp Ther Med. 2013;6:525-31.

15. Faura Giner CC, D’Ocon Navaza P. Medicina Basada en la Evidencia de los AINEs y COXIBs. Act Farm Ter. 2013;11:98-107.

16. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009; 27:2332-41.

17. Rudic RD, Brinster D, Cheng Y, et al. COX-2 derived prostacyclin modulates vascular remodeling. Circ Res. 2005;96:1240-7.

18. Vessières E, Belin de Chantemèle EJ, Toutain B, et al. Cyclooxygenase- 2 inhibition restored endothelium-mediated relaxation in old obese Zucker rat mesenteric arteries. Front Physiol. 2010;1:145.

19. Ferreira-Melo SE, Demacq C, Lacchini S, Krieger JE, Irigoyen MC, Moreno H. Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles. Clinics. 2011;66:1253-8.

20. Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5:19-34.

21. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557-61.

22. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255-8.

23. Stitham J, Midgett C, Martin KA, Hwa J. Prostacyclin: An inflammatory paradox. Front Pharmacol. 2011;2:24.

24. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The Cross Trial Safety Analysis. Circulation. 2008;117:2104-13.

25. Zerbini LF, Tamura RE, Correa RG, et al. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy. PLoS One. 2011;6:e24285.

26. Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition. Circ Res. 2008;102:986-93.

27. Smyth EM. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol. 2010;5:209-19.

28. Boonriong T, Tangtrakulwanich B, Glabglay P, Nimmaanrat S. Comparing etoricoxib and celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial. BMC Musculoskelet Disord. 2010;11:246.